Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data from Cohort 1 in mid-2026 – – Independent Data Monitoring Committee recommended initiation of Cohort 2 at the increased dose of 12 mg/kg in the ELEVATE-44-201 study – – Cash runway expected into Q3 2027 with $296 million in cash, cash equivalents and marketable securities as of December 31, 2025 – BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeu ...